This article is more than 5 years old. Information may no longer be current.

Intravitreal anti-VEGF therapy may be effective for myopic choroidal neovascularization

Retina. 2009;29(6):750-756.

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Three monthly doses of intravitreal ranibizumab produced angiographic closure, improved visual acuity and reduced central foveal thickness in a series of patients treated for choroidal neovascularization secondary to pathologic myopia, according to a study.

Using a protocol of three monthly doses of Lucentis (ranibizumab, Genentech) followed by three additional injections in the presence of persistent or recurrent choroidal neovascularization, researchers noted an improvement from mean best corrected visual acuity of 0.58 logMAR at baseline to 0.39 logMAR at 1 month and 0.28 logMAR at 12 months.

One of 16 patients required the additional dosing regimen at 3 months, while two developed a recurrence between 3 and 9 months.

Optical coherence tomography was performed in 15 or 16 patients; one patient had myopia of –20 D and OCT measurements could not be obtained. Mean central foveal thickness decreased from 292 µm at baseline to 243 µm at 1 month and 233 µm at 6 months.